JP2009528375A5 - - Google Patents

Download PDF

Info

Publication number
JP2009528375A5
JP2009528375A5 JP2008557453A JP2008557453A JP2009528375A5 JP 2009528375 A5 JP2009528375 A5 JP 2009528375A5 JP 2008557453 A JP2008557453 A JP 2008557453A JP 2008557453 A JP2008557453 A JP 2008557453A JP 2009528375 A5 JP2009528375 A5 JP 2009528375A5
Authority
JP
Japan
Prior art keywords
compound
carbon atoms
hydrogen
hydroxy
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008557453A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009528375A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/062574 external-priority patent/WO2007101060A2/en
Publication of JP2009528375A publication Critical patent/JP2009528375A/ja
Publication of JP2009528375A5 publication Critical patent/JP2009528375A5/ja
Pending legal-status Critical Current

Links

JP2008557453A 2006-02-28 2007-02-22 代謝障害を処置するための化合物 Pending JP2009528375A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77767806P 2006-02-28 2006-02-28
PCT/US2007/062574 WO2007101060A2 (en) 2006-02-28 2007-02-22 Compounds for the treatment of metabolic disorders

Publications (2)

Publication Number Publication Date
JP2009528375A JP2009528375A (ja) 2009-08-06
JP2009528375A5 true JP2009528375A5 (OSRAM) 2011-03-03

Family

ID=38459732

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008557453A Pending JP2009528375A (ja) 2006-02-28 2007-02-22 代謝障害を処置するための化合物

Country Status (13)

Country Link
US (2) US20100227901A1 (OSRAM)
EP (1) EP1988772B1 (OSRAM)
JP (1) JP2009528375A (OSRAM)
KR (1) KR20080098615A (OSRAM)
CN (1) CN101394738A (OSRAM)
AT (1) ATE530066T1 (OSRAM)
AU (1) AU2007220868B2 (OSRAM)
CA (1) CA2642662A1 (OSRAM)
IL (1) IL193321A0 (OSRAM)
MX (1) MX2008011022A (OSRAM)
NZ (1) NZ570100A (OSRAM)
WO (1) WO2007101060A2 (OSRAM)
ZA (1) ZA200806444B (OSRAM)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2426005T3 (es) 2004-07-23 2013-10-18 Acceleron Pharma Inc. Polipéptidos del receptor ACTRII, procedimientos y composiciones
EP3811965A1 (en) 2005-11-23 2021-04-28 Acceleron Pharma, Inc. Activin-actriia antagonists in use for promoting bone growth
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
AU2007212104A1 (en) * 2006-02-02 2007-08-16 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
EP2599495A1 (en) 2007-02-01 2013-06-05 Acceleron Pharma, Inc. Activin-ActRIIa Antagonists and Uses for Treating or Preventing Breast Cancer
TW201940502A (zh) 2007-02-02 2019-10-16 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
KR20200054317A (ko) 2007-02-09 2020-05-19 악셀레론 파마 인코포레이티드 액티빈-ActRⅡA 길항제 및 암 환자에서 골 생장을 촉진시키기 위한 이의 용도
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CA2699936A1 (en) 2007-09-18 2009-03-26 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
US8481595B2 (en) * 2008-01-15 2013-07-09 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
HUE051137T2 (hu) 2008-08-14 2021-03-01 Acceleron Pharma Inc GDF-csapdák
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
US8178488B2 (en) 2009-06-08 2012-05-15 Acceleron Pharma, Inc. Methods for increasing thermogenic adipocytes
EP2440577A4 (en) 2009-06-12 2013-01-23 Acceleron Pharma Inc SHORTEN ACTRIIB FC FUSION PROTEINS
EP3260130B1 (en) * 2009-11-03 2021-03-10 Acceleron Pharma Inc. Methods for treating fatty liver disease
US8710016B2 (en) 2009-11-17 2014-04-29 Acceleron Pharma, Inc. ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
DE102010015123A1 (de) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
CN103298832A (zh) 2010-11-08 2013-09-11 阿塞勒隆制药公司 Actriia结合剂及其用途
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8500260B2 (en) 2011-04-27 2013-08-06 Xerox Corporation Ink compositions incorporating substituted oxazoline compounds or substituted oxazoline derivatives
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US10195249B2 (en) 2012-11-02 2019-02-05 Celgene Corporation Activin-ActRII antagonists and uses for treating bone and other disorders
CN107135646B (zh) 2014-06-13 2022-03-15 阿塞勒隆制药公司 用于治疗溃疡的方法和组合物
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
JP2018501307A (ja) 2014-12-03 2018-01-18 セルジーン コーポレイション アクチビン−ActRIIアンタゴニスト及び貧血を治療するための使用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4824843A (en) * 1987-06-25 1989-04-25 Warner-Lambert Company Substituted amide inhibitors of cholesterol absorption
JP3906935B2 (ja) * 1995-12-18 2007-04-18 杏林製薬株式会社 N−置換ジオキソチアゾリジルベンズアミド誘導体及びその製造法
US6555536B2 (en) * 2000-05-12 2003-04-29 Ortho-Mcneil Pharmaceutical, Inc. Biologically active 4H-benzo [1,4]oxazin-3-ones
MXPA03011558A (es) * 2001-06-12 2004-03-26 Wellstat Therapeutics Corp Compuestos para el tratamiento de desordenes metabolicos.
WO2004041165A2 (en) * 2002-11-01 2004-05-21 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
BRPI0407506A (pt) * 2003-02-13 2006-02-14 Wellstat Therapeutics Corp compostos para o tratamento de distúrbios metabólicos, seu uso e composição farmacêutica compreendendo os mesmos
PL1633340T3 (pl) * 2003-04-15 2011-04-29 Wellstat Therapeutics Corp Związki do leczenia chorób metabolicznych
CN1777576A (zh) * 2003-04-22 2006-05-24 维尔斯达医疗公司 用于治疗代谢紊乱的化合物
AU2004237602B2 (en) * 2003-04-30 2009-05-28 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
WO2005018628A1 (en) * 2003-08-20 2005-03-03 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders

Similar Documents

Publication Publication Date Title
JP2009528375A5 (OSRAM)
JP2009531280A5 (OSRAM)
JP2009528275A5 (OSRAM)
JP2009537559A5 (OSRAM)
CA2513092A1 (en) Compounds for the treatment of metabolic disorders
CA2521621A1 (en) Compounds for the treatment of metabolic disorders
JP2006524252A5 (OSRAM)
CA2522738A1 (en) Compounds for the treatment of metabolic disorders
JP6238460B2 (ja) 脂質異常症治療剤
CA2521589A1 (en) Compounds for the treatment of metabolic disorders
JP2011519865A5 (OSRAM)
RU2008123000A (ru) Соединения для лечения метаболических нарушений
JP2004524312A5 (OSRAM)
JP2009530398A5 (OSRAM)
RU2004105956A (ru) Новые производные винилкарбоновых кислот и их применение в качестве антидиабетических средств и т.п.
RU2010141823A (ru) Соединения и способ снижения мочевой кислоты
JP2005526696A5 (OSRAM)
JP2009524686A5 (OSRAM)
RU2006108572A (ru) Соединения для лечения метаболических нарушений
CN1159305C (zh) 新的2-(n-氰基亚氨基)噻唑烷-4-酮衍生物
JP2004508399A5 (OSRAM)
JP2009528997A5 (OSRAM)
EP1868595B1 (en) Compounds for the treatment of metabolic disorders
EP1569904B1 (en) Substituted arylalcanoic acid derivatives as ppar pan agonists with potent antihyperglycemic and antihyperlipidemic activity
CN1162152C (zh) 糖尿病治疗剂